We, at Piramal Pharma Limited, offer a portfolio of diversified products and services through end-to-end manufacturing capabilities across 15 global facilities and a global distribution network, spanning over 100 countries. We are dedicated to enhancing healthcare worldwide through collaborations with market leaders to bring innovative and quality solutions to customers. PPL includes: Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization (CDMO); Piramal Critical Care (PCC), a Complex Hospital Generics (CHG) business, and the India Consumer Healthcare business (ICH), selling over the-counter products in India. In addition, PPL has a joint venture with Allergan (now AbbVie), a leader in ophthalmology in the Indian formulations market.
Piramal Pharma business segments
Complex Hospital Generics
Piramal Critical Care’s complex hospital generics portfolio includes
inhalation anaesthetic, intrathecal therapies for spasticity and
pain management, injectable pain and anaesthetic, injectable
anti-infectives, and other therapies. We are one of the few major
suppliers of inhaled anaesthesia with capability to manufacture
all four generations of inhalation anaesthetic products. Our strong
marketing capabilities allow us to distribute products in over 100
countries with direct sales presence in the US, the UK, Italy and
Germany. Our portfolio and pipeline are expanding within the
business segment, with multiple products in various stages of
development.
Contract Development and Manufacturing Organisation
Piramal Pharma Solutions, an integrated Contract Development
and Manufacturing Organisation, is involved in integrated drug
discovery, development, and manufacturing services for both,
APIs and formulations from the start of product lifecycle to its
commercial launch and supply. Our global CDMO operations
offer end-to-end solutions through an integrated network of
facilities across the drug lifecycle for both, innovators and generic
companies. It houses strong capabilities in Highly Potent APIs
(HPAPIs), Antibody Drug Conjugates (ADCs), Peptide APIs, potent
sterile injectables, biologics and vaccines. Our development and
manufacturing facilities are in India, the UK, the US, and Canada.
These manufacturing facilities are approved by global
pharma regulatory agencies including USFDA (Food and Drug
Administration), UK MHRA (Medicines and Healthcare Products
Regulatory Agency), Japan PMDA (Pharmaceuticals and Medical
Devices Agency), ANVISA (Brazilian Health Regulatory Agency),
and Health Canada, to supply products to respective markets.
They cater to a wide customer base across the world, including
global big pharma companies, emerging biopharma companies,
and generic pharma companies.
India Consumer Healthcare
PPL’s ICH business is one of India’s major self-care companies,
with well-known products in the Indian consumer healthcare
sector. Our marquee brands include Little’s, Lacto Calamine,
I-Pill, Polycrol, Tetmosol, Saridon and Supradyn across key OTC
categories, such as Baby Care, Skin Care, Women Care and
Allergy Management, Gastrointestinal (GI), Vitamins, Minerals,
and Supplements (VMS) and Analgesics. We have a wide market
presence across India, with presence in ~200,000 chemists and
cosmetics stores, and 10,000+ kids, toys and gift shops, covering
all key markets.
Joint venture with Allergan (now AbbVie)
Allergan India Private Limited, a joint venture between Allergan and PPL, commenced commercial operations in 1996.
Allergan India is a specialty pharmaceutical company. It has emerged as the market leader in the fast-growing ophthalmic
category with the successful launches of a series of high technology medication and devices for diseases, such as glaucoma,
dry eye, infections, and inflammations. PPL owns 49% equity stake in Allergan India Private Limited. Poised to grow at
a rapid pace, Allergan India today is the partner of choice for majority of the ophthalmologists in the country, and an
undisputed leader in the eyecare pharma market, with dominance in all major disease segments.
| Subscribe To Our Free Newsletter |
